Figure 1. Canonical (C481S) and variant mutations reported in patients assessed for BTK mutations. Mutations reported after prior therapy with IBR, ACALA, ZANU, PIRTO, or BGB-16673, and potential paths of cross-resistance. ACALA, acalabrutinib; IBR, ibrutinib; PIRTO, pirtobrutinib; ZANU, zanubru... More about this image found in Canonical (C481S) and variant mutations reported in patients assessed for B...

Figure 1. Overview of differentiation pathways of monocytes and TRMs. TRM populations arise via distinct differentiation pathways, derived from either erythromyeloid progenitors or monocytes generated from the BM. Common myeloid progenitors in the BM generate lineage-restricted granulocyte-monoc... More about this image found in Overview of differentiation pathways of monocytes and TRMs. TRM population...

Figure 2. Sites of activity of inhibitors of the CSF1 signaling pathway. CSF1 and IL-34 signal through the class 3 receptor tyrosine kinase CSF1R to regulate monocyte and macrophage differentiation and survival. CSF1-neutralizing antibodies bind to the circulating ligand to prevent receptor bind... More about this image found in Sites of activity of inhibitors of the CSF1 signaling pathway. CSF1 and IL...

Figure 3. Contribution of macrophages to cGVHD pathology and therapeutic benefit of CSF1R antibody blockade. IL-17 production from T helper 17 (Th17)/Tc17 cells functions as a chemoattractant for Ly6C lo monocytes, which subsequently differentiate into CD206 + macrophages in the presence of CS... More about this image found in Contribution of macrophages to cGVHD pathology and therapeutic benefit of C...

Figure 4. Functions of monocytes and macrophages in CAR T-cell–related complications. In the periphery, CAR T-cell engagement with target antigen leads to release of cytokines including GM-CSF and IFN-γ causing the robust activation of proinflammatory macrophages. Macrophages contribute to the r... More about this image found in Functions of monocytes and macrophages in CAR T-cell–related complications....

Figure 1. The specificities and affinities of anti-CD7 VHH antibodies. (A) FCM of anti-CD7 VHH antibodies binding recognizing CD7 + cell lines. K562-CD7 is a CD7-overexpressing cell line. CCRF-CEM is a CD7 + T-ALL cell line. KG1a is a CD7 + AML cell line. (B) Specificity of dVHH was profiled ... More about this image found in The specificities and affinities of anti-CD7 VHH antibodies. (A) FCM of an...

Figure 2. In vitro and in vivo analysis of dVHH NS7CAR-Ts. (A) Schematic representation of the scFv NS7CAR and VHH NS7CAR constructs. (B-E) A comparison of the fold cell expansion, cell viability, CAR-positive rate, and CD4:CD8 ratio between scFv NS7CAR-Ts and dVHH NS7CAR-Ts. Data are presented ... More about this image found in In vitro and in vivo analysis of dVHH NS7CAR-Ts. (A) Schematic representat...

Figure 3. Clinical response to dVHH NS7CAR-T therapy. Swimmer plot showing responses of individual patients (pts) infused with dVHH NS7CAR-Ts on the last follow-up date. After NS7CAR-T therapy, 7 of 10 pts achieved CRi, 6 of whom attaining MRD-negative CRi. Three pts (pt 4, pt 9, and pt 10) show... More about this image found in Clinical response to dVHH NS7CAR-T therapy. Swimmer plot showing responses...

Figure 4. Expansion of dVHH NS7CAR-Ts in the PB. (A) After infusion, the median peak of circulating NS7CAR-Ts was 64.68% (40.08% to ∼92.02%), which occurred on day 17 (day 11-21). (B) By quantitative PCR (qPCR), the median peak of NS7CAR-Ts was 2.72 × 10 5 copies per μg genomic DNA (range, 0.67... More about this image found in Expansion of dVHH NS7CAR-Ts in the PB. (A) After infusion, the median peak...

Figure 1. Kaplan-Meier estimated LCH-HI patient survival in France during the years after diagnosis (Dx). (A) All patients with LCH-HI from 1983 to 2023, with shaded 95% CI. (B) Three groups, corresponding to major therapeutic management changes, according to diagnosis year: blue, <1998; red,... More about this image found in Kaplan-Meier estimated LCH-HI patient survival in France during the years a...